References
- Hughes IA, Houk C, Ahmed SF, et al. Consensus statement on the management of intersex disorders. Arch Dis Child 2006;91:554–63
- Hersmus R, Stoop H, White SJ, et al. Delayed recognition of disorders of sex development (DSD): a missed opportunity for early diagnosis of malignant germ-cell tumors. Int J Endocrinol 2012;2012:671209. doi: 10.1155/2012/671209
- Pleskacova J, Hersmus R, Oosterhuis JW, et al. Tumor risk in disorders of sex development. Sex Dev 2010;4:259–69
- Juniarto AZ, Setyawati BA, Miranti IP, et al. Gonadal malignancy in 13 consecutive collected patients with disorders of sex development (DSD) from Semarang (Indonesia). J Clin Pathol 2013;66:198–204
- Looijenga LH, Hersmus R, de Leeuw BH, et al. Gonadal tumors and SDD. Best Pract Res Clin Endocrinol Metab 2010;24:291–310
- Verp MS, Simpson JL. Abnormal sexual differentiation and neoplasia. Cancer Genet Cytogenet 1987;25:191–218
- Cools M, Drop SL, Wolffenbuttel KP, et al. Germ-cell tumors in the intersex gonad: old paths, new directions, moving frontiers. Endocr Rev 2006;27:468–84
- Looijenga LH, Hersmus R, Oosterhuis JW, et al. Tumor risk in disorders of sex development (DSD). Best Pract Res Clin Endocrinol Metab 2007;21:480–95
- Wunsch L, Holterhus PM, Wessel L, Hiort O. Patients with disorders of sex development (DSD) at risk of gonadal-tumor development: management based on laparoscopic biopsy and molecular diagnosis. BJU Int 2012;110:e958–65
- Abaci A, Catli G, Berberoglu M. Gonadal-malignancy risk and prophylactic gonadectomy in disorders of sexual development. J Pediatr Endocrinol Metab 2015;28:1019–27
- Manuel M, Katayama PK, Jones HW. The age of occurrence of gonadal tumors in intersex patients with a Y-chromosome. Am J Obstet Gynecol 1976;124:293–300
- Michala L, Goswami D, Creighton SM, Conway GS. Swyer syndrome: presentation and outcomes. BJOG 2008;115:737–41
- Deans R, Creighton SM, Liao LM, Conway GS. Timing of gonadectomy in adult women with complete androgen-insensitivity syndrome (CAIS): patient preferences and clinical evidence. Clin Endocrinol (Oxf) 2012;76:894–8
- Hughes IA, Davies JD, Bunch TI, et al. Androgen insensitivity syndrome. Lancet 2012;380:1419–28
- Cools M, Pleskacova J, Stoop H, et al. Gonadal pathology and tumor risk in relation to clinical characteristics in patients with 45, X/46, XY mosaicism. J Clin Endocrinol Metab 2011;96:e1171–80
- Hughes IA, Deeb A. Androgen resistance. Best Pract Res Clin Endocrinol Metab 2006;20:577–98
- Mendoza N, Motos MA. Androgen insensitivity syndrome. Gynecol Endocrinol 2013;29:1–5
- Nakhal RS, Hall-Craggs M, Freeman A, et al. Evaluation of retained testes in adolescent girls and women with complete androgen-insensitivity syndrome. Radiology 2013;268:153–60
- Liu AX, Shi HY, Cai ZJ, et al. Increased risk of gonadal malignancy and prophylactic gonadectomy: a study of 102 phenotypical female patients with Y-chromosome or Y-derived sequences. Hum Reprod 2014;29:1413–19
- Griffin JE. Androgen resistance: the clinical and molecular spectrum. N Engl J Med 1992;326:611–18
- Zhang M, Sun S, Liu Y, et al. New, recurrent, and prevalent mutations: clinical and molecular characterizations of 26 Chinese patients with 17 alpha-hydroxylase/17, 20-lyase deficiency. J Steroid Biochem Mol Biol 2015;150:11–16
- Yao F, Huang S, Kang X, et al. CYP17A1 mutations identified in 17 Chinese patients with 17 alpha-hydroxylase/17, 20-lyase deficiency. Gynecol Endocrinol 2013;29:10–15
- Kim SM, Rhee JH. A case study of 17 alpha-hydroxylase deficiency. Clin Exp Reprod Med 2015;42:72–6
- Brooke AM, Taylor NF, Shepherd JH, et al. A novel point mutation in P450c17 (CYP17) causing a combined 17 alpha-hydroxylase/17, 20-lyase deficiency. J Clin Endocrinol Metab 2006;91:2428–31
- Ahmed SF, Bashamboo A, Lucas-Herald A, McElreavey K. Understanding genetic etiology in patients with XY DSD. Br Med Bull 2013;106:67–89